1 Correction to: Drugs (2019) 79 (12):1355–1361 https://doi.org/10.1007/s40265-019-01167-0
Page 1355, Abstract, Inline table ‘Camrelizumab (AiRuiKa™): Key Points’, and Introduction
Where it currently reads Camrelizumab (AiRuiKa™), it should read:
Camrelizumab (AiRuiKa®).
Page 1355, Inline table ‘Camrelizumab (AiRuiKa™): Key Points’
The third row, which currently reads:
First global approval on 31 May 2019 in China.
Should read:
First global approval on 29 May 2019 in China.
Page 1361, Section 3 Current Status, which currently reads:
Camrelizumab received its first global approval on the 31 May 2019 in China for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least two previous systemic chemotherapies.
Should read:
Camrelizumab received its first global approval on the 29 May 2019 in China for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma who have received at least two previous systemic chemotherapies.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Markham, A., Keam, S.J. Correction to: Camrelizumab: First Global Approval. Drugs 79, 1497 (2019). https://doi.org/10.1007/s40265-019-01191-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-019-01191-0